Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11620)	11/24/1997 1:11:00 PM
From: Andrew H	Respond to of 32384

>>Andy, I agree with you that $20 is just around the corner.<< I did say that, didn't I? Still its not going to happen in time for you to win the bet. Better start shopping for wine!! The NBC story IS very interesting; too bad it didn't get pciked up by more stations. Your 1550 guess sounds like a good one. If that's the case, it would be nice to have a release from LGND detailing the results. >>A new SEC filing on ALRT is also a signal that the buyback is about to be finalized, paving the way for closure of the LLY deal and selction of the new compound<< About time the SEC got their stuff together. I guess they must have had too many of their agents watching you!! (:>) Let's hope this will get rid of the arbitrageurs. About 3M more shares out now, which would account for a roughly 10% decline in the stock price. If we add the roughly 12% drop in biotechs, that just about accounts for LGND's decline. I agree the Panretin results should be good and lead to a fast tracked NDA, altho the KS market is limited. Hopefully we will get some good news about the P2 psoriasis trials which SA mentioned were still in progress. Clearly LGND has a great record for picking compounds that get through trials rapidly and effectively. >>LGND's current price is less than ideal, but considerably better than others. AMLN set a 52-week low last week, at 6 1/2. LGND and AMLN prices were very close before AMLN released Phase III data on Pramlintide. In contrast, I expect Panretin phase III data to be very favorable.<< Henry, I really don't think we want to compare LGND with AMLN. (:>). Kind of like comparing a one trick pony with Ron Evans.